The estimated Net Worth of Julie Mc Hugh is at least $4.12 million dollars as of 10 June 2024. Ms. Hugh owns over 22,766 units of Aerie Pharmaceuticals Inc stock worth over $2,127,802 and over the last 11 years she sold AERI stock worth over $1,666,345. In addition, she makes $326,746 as Independent Director at Aerie Pharmaceuticals Inc.
Sign up
Ms. McHugh AERI stock SEC Form 4 insiders trading
Julie has made over 19 trades of the Aerie Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 22,766 units of AERI stock worth $143,198 on 10 June 2024.
The largest trade she's ever made was selling 22,766 units of Aerie Pharmaceuticals Inc stock on 10 June 2024 worth over $143,198. On average, Julie trades about 1,472 units every 39 days since 2014. As of 10 June 2024 she still owns at least 139,528 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Ms. Hugh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Julie McHugh biography
Julie H. McHugh serves as Independent Director of the Company. Ms. McHugh served as Chief Operating Officer of Endo Health Solutions, Inc. from March 2010 until her retirement in May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to this, Ms. McHugh was Chief Executive Officer of Nora Therapeutics, Inc., a venture capital backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Previously, Ms. McHugh served as Company Group Chairman for Johnson & Johnson’s worldwide virology business unit, and prior to this, she was President of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine). Prior to joining Centocor, Ms. McHugh led marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves as chair of the board of directors of Ironwood Pharmaceuticals, Inc. and member of the board of directors of Lantheus Holdings, Inc., New Xellia Group A/S, and Trevena Pharmaceuticals, Inc. Ms. McHugh previously served on the board of directors of the Biotechnology Industry Organization (BIO), the New England Healthcare Institute (NEHI), the Pennsylvania Biotechnology Association, EPIRUS Biopharmaceuticals, Inc. and ViroPharma Inc. Ms. McHugh received her M.B.A. from St. Joseph’s University and her B.S. from Pennsylvania State University.
What is the salary of Julie McHugh?
As the Independent Director of Aerie Pharmaceuticals Inc, the total compensation of Julie McHugh at Aerie Pharmaceuticals Inc is $326,746. There are 12 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of $5,529,670.
How old is Julie McHugh?
Julie McHugh is 55, she's been the Independent Director of Aerie Pharmaceuticals Inc since 2015. There are 16 older and 4 younger executives at Aerie Pharmaceuticals Inc. The oldest executive at Aerie Pharmaceuticals Inc is Gerald Cagle, 75, who is the Independent Director.
What's Julie McHugh's mailing address?
Julie's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.
Insiders trading at Aerie Pharmaceuticals Inc
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra et Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
What does Aerie Pharmaceuticals Inc's logo look like?
Complete history of Ms. Hugh stock trades at Aerie Pharmaceuticals Inc, Ironwood Pharmaceuticals Inc, Lantheus Inc, Trevena Inc et Evelo Biosciences Inc
Aerie Pharmaceuticals Inc executives and stock owners
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Vicente Anido,
Chairman of the Board, Chief Executive Officer -
Thomas Mitro,
President, Chief Operating Officer -
John LaRocca,
General Counsel and Assistant Secretary -
Richard Rubino,
Chief Financial Officer, Treasurer, Secretary -
Casey Kopczynski,
Co-Founder, Chief Scientific Officer -
Raj Kannan,
CEO, Principal Financial Officer & Director -
Thomas A. Mitro,
Pres & COO -
Dr. Casey C. Kopczynski,
Co-Founder & Chief Scientific Officer -
John W. LaRocca Esq.,
Gen. Counsel & Sec. -
Dr. David A. Hollander M.B.A., M.D.,
Chief R&D Officer -
Benjamin McGraw,
Lead Independent Director -
Gerald Cagle,
Independent Director -
Julie McHugh,
Independent Director -
David Gryska,
Independent Director -
Mechiel Du Toit,
Independent Director -
Richard Croarkin,
Independent Director -
Dr. Benjamin F. McGraw III, J.D., Pharm.D.,
Exec. Chairman -
Peter McDonnell,
Director -
David Hollander,
Chief Research and Development Officer -
Nina Ohara,
Director of Marketing -
Craig R. Skenes,
Head of Bus. Devel. -
Marvin J. Garrett,
Head of Regulatory Affairs & Quality Assurance -
Wanda Francies,
Head of HR -
Jeffrey M. Calabrese CPA,
VP of Fin. & Principal Accounting Officer -
Dr. Michelle Senchyna Ph.D.,
Head of Clinical Devel. & Operations -
Peter F. Lang,
Chief Financial Officer -
Carolyn McAuliffe,
Sr. Director of Communications -
Evan Hockman,
VP of Sales -
Tad Heitmann,
Head of Communications -
Andrew Allen,
Chief Compliance Officer -
Ami Bavishi,
Director of Investor Relations -
Jeffrey Calabrese,
Director of Accounting -
Toit Michael Du,
Director -
Murray A Goldberg,
Director -
Capital Management Ii, Llc ...,
-
Geoffrey M Duyk,
Director -
Capital Management Ii, Llc ...,
-
Capital Management Ii, Llc ...,
-
James E Deerfield Mgmt L.P....,
-
Anand Healy Jamespowell Mic...,
-
James V Mazzo,
Director -
Group Holdings (Sbs) Adviso...,
-
Brian Levy,
Chief Medical Officer -
Venture Partners Vii L P So...,
-
Iv, L.P.Acmp Iv Llcjanney D...,
-
Lifesciences Ii, L.P.Clarus...,
-
Iv, L.P.Janney Danielnohra ...,
-
Anand Mehra,
Director -
Peter Frederick Lang,
Chief Financial Officer -
Capital Management Iv, Llc ...,
-
Capital Management Ii, Llc ...,
-
Jeffrey Calabrese,
Vice President of Finance -
Christopher Staten,
Interim CFO -
Raj Kannan,
Chief Executive Officer -
Kathleen Mcginley,
CHRO & VP, Corp Services